OrbusNeich Medical (Booth 1011) is highlighting data from clinical trials of its Genous bio-engineered R stent, which is not commercially available in the U.S., to prevent thrombosis and minimize restenosis.

Robbert de Winter, MD, PhD, of the Academic Medical Center in Amsterdam will provide a Genous clinical program update in an oral presentation at 4:10 pm on Monday, Oct. 13 in Ballroom C, including interim follow-up data from e-HEALING, a monitored, multi-center, global prospective registry with 5,000 enrolled patients.  

The Genous drug-eluting stent, which is coated with an antibody, captures a patient’s endothelial progenitor cells (EPCs) to accelerate the natural healing process. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.